Table 1.
Radiological evaluation by MRI and FDG-PET/CT in patients with disseminated malignant melanoma treated with AdCD40L.
| MRI evaluation (RECIST 1.1) | PET evaluation (EORTC criteria) | |||
|---|---|---|---|---|
| Patient no | Week 5 | Week 9 | Week 5 | Week 9 |
| Scan 1 | Scan 2 | Scan 1 | Scan 2 | |
| Without cyclophosphamide | ||||
| 1 | PD | — | SMD | — |
| 2 | PD | — | PMR | PMR |
| 3 | SD | PD | PMR | — |
| 4 | SD | SD | SMD | SMD |
| 5 | SD | SD | SMD | SMD |
| 6 | PD | — | SMD | — |
| With cyclophosphamide | ||||
| 7 | SD | SD | SMD | SMD |
| 8 | SD | SD | PMR | SMD |
| 9 | PD | — | PMR | — |
| 10 | SD | SD | SMD | SMD |
| 11 | — | — | — | — |
| 12 | PD | PD | SMD | PMR |
| 13 | PD | PD | PMD | SMD |
| 14* | SD | PD | SMD | SMD |
| 15 | PD | PD | SMD | SMD |
| With cyclophosphamide and irradiation | ||||
| 16 | PD | PD | PMD | PMD |
| 17 | SD | PD | SMD | PMR |
| 18 | SD | SD | PMR | PMR |
| 19 | SD | SD | PMD | PMD |
| 20 | SD | SD | PMR | PMR |
| 21 | PD | — | SMD | — |
| 22 | — | — | — | — |
| 23 | — | — | — | — |
| 24* | PD | PD | PMD | PMD |
Abrreviations: – = not done; SD = stable disease; PD = progressive disease; PMD = progressive metabolic disease; PMR = partial metabolic response; SMD = stable metabolic disease.
Treatment response assessments by RECIST 1.1. and EORTC criteria. *Due to technical issues the DWI-data were not available.